Abstract
The management of metastatic hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–positive (HER2+) breast cancer continues to evolve with the development of novel targeted therapies. At JADPRO Live, presenters discussed therapies for this subtype of breast cancer, adverse events, management strategies, as well as biomarkers to consider when making treatment decisions.
